PARLIAMENTARY WRITTEN QUESTION
(13 May 2026)

To ask the Secretary of State for Health and Social Care, whether the transformation of liver services programme led by the NHS England Hepatobiliary and Pancreas Clinical Reference Group will include a specific workstream to help address the unmet clinical need in metabolic dysfunction-associated steatohepatitis.

Asked by:
Steve Yemm (Labour)

The transformation of liver services programme includes a number of workstreams including patient pathways relating to metabolic associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASH).

NHS England is actively preparing to support the potential introduction of new treatments for MASH, including fatty liver disease with fibrosis, alongside the ongoing National Institute for Health and Care Excellence appraisal process.

Answered by:
()